此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).

2016年4月8日 更新者:Hoffmann-La Roche

Relationships Between Pharmacokinetic and Pharmacodynamic Strategies for Assessment of the Risks for Acute Rejection and Side Effects of Mycophenolate Mofetil

This study will evaluate the correlation between the pharmacokinetic and pharmacodynamic parameters of CellCept in patients undergoing primary kidney transplantation, in order to assess the impact on clinical outcome and the risks of acute rejection. All patients will receive oral CellCept, 1g twice daily, and pharmacokinetic and pharmacodynamic parameters will be measured at weeks 2, 4, 12 and 24. The anticipated time on study treatment is 24 weeks.

研究概览

研究类型

介入性

注册 (实际的)

45

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bari、意大利、70124
      • Brescia、意大利、25123
      • Coppito、意大利、67100
      • Napoli、意大利、80131
      • Roma、意大利、00168
      • Torino、意大利、10126
      • Verona、意大利、37126

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult patients, 18 to 65 years of age
  • Patients undergoing primary kidney transplantation

Exclusion Criteria:

  • Recipients of multiple organ transplants
  • Prior therapy with CellCept
  • Presence or history of malignancies, except for successfully treated basal or squamous cell carcinoma of the skin
  • Active peptic ulcer or active serious digestive system disease that may affect the absorption of CellCept

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Mycophenolate Mofetil Monotherapy
Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
1 g PO BID for 24 weeks
其他名称:
  • 细胞概念
According to manufacturer recommendation
According to manufacturer recommendation
According to manufacturer recommendation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants With Acute Rejection
大体时间:Day 1, Weeks 2, 4, 12, 24, and 28
Diagnosis of acute rejection was suspected in any participant with an increase in serum creatinine greater than or equal to (≥) 25 percent (%). All suspected acute rejections were confirmed by biopsy. The start date of acute rejection was identified as the date of biopsy.
Day 1, Weeks 2, 4, 12, 24, and 28
Time to Rejection
大体时间:Day 1, Weeks 2, 4, 12, 24, and 28
The mean time, in days, from the date of enrollment to date of biopsy confirming acute rejection.
Day 1, Weeks 2, 4, 12, 24, and 28
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)
大体时间:Day 1, Weeks 2, 4, 12, 24, and 28
BPAR was defined according to 1997 Banff Criteria as a biopsy Banff grade of IA, IB, IIA, IIB, or III. Grade IA was defined as significant interstitial infiltration with greater than (>)25% of parenchyma affected, and foci of moderate tubulitis with >4 mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IB was defined as significant interstitial infiltration with >25% parenchyma affected, and foci of severe tubulitis with >10% mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IIA was defined as mild to moderate intimal arteritis. Grade IIB was defined as severe intimal arteritis comprising >25% of the luminal area. Grade III was defined as transmural arteritis and/or arterial fibrinoid changes and necrosis of medial smooth muscle cells.
Day 1, Weeks 2, 4, 12, 24, and 28

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants With Graft Loss
大体时间:Day 1, Weeks 2, 4, 12, 24, and 28
An allograft was presumed to be lost if a participant started dialysis and was not able to subsequently be removed from dialysis.
Day 1, Weeks 2, 4, 12, 24, and 28
Percentage of Participants Surviving
大体时间:Day 1, Weeks 2, 4, 12, 24, and 28
Day 1, Weeks 2, 4, 12, 24, and 28
Total Mycophenolate Acid (MPA) by Visit and Timepoint
大体时间:Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits
Drug quantification of total MPA (micrograms per milliliter [mcg/mL]) in the plasma was measured at time (T) = 0 minutes (min), 40 mins, and 120 mins.
Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits
Free MPA (mcg/mL) by Visit
大体时间:Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits
Drug quantification of free MPA in the plasma was measured at T = 0, 40, and 120 mins.
Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits
MPA Area Under the Concentration - Time Curve From Time 0 to 12 Hours (AUC0-12) (mcg/mL) by Visit
大体时间:Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)
The AUC0-12 of MPA was estimated on the validated limited sampling strategy, AUC (milligrams multiplied by height over liter [mg.h/L]) = 7.182 + 4.607 multiplied by (*) concentration at 0 minutes (C0)+ 0.998 * the concentration at 40 minutes (C0.67) + 2.149 * the concentration at 120 minutes (C2).
Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)
Inosine MonoPhosphate DeHydrogenase (IMPDH) Activity by Visit and Timepoint
大体时间:BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
IMPDH activity in peripheral blood mononuclear cells (PBMCs) was measured at 2 timepoints per visit, 0 and 120 minutes and presented in enzyme units. The unit of measure of enzyme activity is "U". One U is defined as the amount of the enzyme that produces a certain amount of enzymatic activity that is, the amount that catalyzes the conversion of 1 micro mole of substrate per minute under pre-specified conditions (temperature, pH).
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
IMPDH Expression I by Visit and Timepoint
大体时间:BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
IMPDH I gene expression was measured by real time polymerase chain reaction (QRT-PCR) based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of messenger ribonucleic acid (mRNA) copies per cell (copies/cell).
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
IMPDH Expression II by Visit and Timepoint
大体时间:BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
IMPDH II gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
Interleukin 8 (IL-8) Expression by Visit and Timepoint
大体时间:BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
IL-8 gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
Tumor Necrosis Factor (TNF) Expression by Visit and Timepoint
大体时间:BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
TNF gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
Percentage of Participants With Infection
大体时间:BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
Infections were graded according to the World Health Organization (WHO) worst grade observed.
BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
Percentage of Participants With Gastrointestinal Toxicities
大体时间:BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)
Gastrointestinal adverse events (AEs) according to WHO worst grade observed.
BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)
Percentage of Participants With Hematologic Toxicity
大体时间:BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
Hematological toxicities graded according to WHO worst grade observed (Grade 1=mild, Grade 2=moderate).
BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
Spearman's Rank Correlation Coefficient Between MPA Levels and IMPDH Activity
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH I Expression and MPA Levels
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH I Expression and Free Fraction
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH II Expression and MPA Levels
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH II Expression and Free Fraction
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH Inhibition and Risk of Acute Rejection
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Infection
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Hematologic Toxicity
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Gastrointestinal Toxicity
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Infection
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Hematologic Toxicity
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24
Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Gastrointestinal Toxicity
大体时间:BL and Weeks 2, 4, 12, and 24
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.
BL and Weeks 2, 4, 12, and 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年12月1日

初级完成 (实际的)

2008年9月1日

研究完成 (实际的)

2008年9月1日

研究注册日期

首次提交

2011年2月3日

首先提交符合 QC 标准的

2011年2月8日

首次发布 (估计)

2011年2月9日

研究记录更新

最后更新发布 (估计)

2016年5月12日

上次提交的符合 QC 标准的更新

2016年4月8日

最后验证

2016年4月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅